Johan Van Hoof, M.D., is COO (2011) and managing director (2012) for the vaccine company Crucell (Holland BV), and global therapeutic area head, infectious diseases & vaccines group (2010) for Johnson & Johnson Family of Companies (J&J). In his role as COO and managing director, Van Hoof oversees research and development. As of January 2015, Van Hoof’s focus has been on prevention through vaccination, which is one of the most cost-effective health interventions. Van Hoof joined J&J in April 2005 as vice president for data management and early clinical development. Over time, he had increasing responsibilities, including COO and head of the global development organization for J&J Pharmaceutical Research LLC.
Before joining J&J, Van Hoof acquired more than 20 years of experience in the vaccine industry, working with Pasteur Mérieux Connaught (now Sanofi Pasteur), Chiron Vaccines (now Novartis) and GlaxoSmithKline Biologicals (GSK). During this period, he held leadership roles with increasing responsibilities, including head new product development at GSK Biologicals. Van Hoof was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis (pediatric combined vaccines), meningitis, rotaviral diarrhea, hepatitis, flu and HPV.
Van Hoof received his M.D. (cum lauda) from the University of Antwerp and was a research fellow in the department of anatomy and embryology at Rijksuniversitair Centrum (Antwerpen, Belgium). Van Hoof studied business management at Krauthammer International School and the International Executive Program INSEAD (Fontainebleau, France).